Translational individualised medicine: inflammation and cancer

2022 Activity indicators

  • 1 European project coordinated: REACT-EU "MITICAD-CM"- ERDF 
  • 7 private projects led
  • 3 competitive HR contracts
  • 49 publications
  • IF: 174,69
  • D1 publications: 3 (6 %)
  • Q1 publications: 18 (37 %)
  • 2 supervised doctoral theses
  • Evaluators of Public Research Agencies: 2 PI.
  • Members of Editorial Committees: 1 PI.

Milestones

  1. Competitive multicentre project in the European response against the COVID-19 pandemic financed by the Community of Madrid with FEDER funds entitled "Individualised and translational medicine in patients with COVID-19 and post-COVID: Diagnostic, therapeutic and preventive implications. Optimisation of healthcare practice in Medicine and Health Sciences in the pandemic environment (MITICAD-CM)".
  2. Defended doctoral thesis of a young clinical researcher with quality indexes, with more than 6 publications in JCR.
  3. Award of an AES22 Health Research Project entitled "Social consideration and characterisation of patterns in the abuse of opioid drugs (PI22/00653)".
  4. Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol. 2022; 19(2):112-134. doi: 10.1038/s41575-021-00520-7. PMID: 34703031.
  5. Intense sponsorship activities with more than half a million euros in clinical and translational research.

Bibliometrics

  ARTICLES ACCUM. IF MEAN IF ARTICLES Q1 OR Q2 % IN Q1 OR Q2 ARTICLES D1 % IN D1
2018 9 38,11 4,23 11 122 2 22
2019 12 58,56 4,88 10 83 2 17
2020 14 59,21 4,23 13 93 1 7
2021 40 174,69 4,48 34 85 4 10
2022 49 307,13 6,27 42 86 3 6
  124 637,69 4,82 110 89 12 10

Networks and alliances

  • CIBER de Enfermedades Hepáticas y Digestivas (CIBERehd)
  • Programa Medicina Individualizada Traslacional en Inflamación y Cáncer (MITIC-CM)